Clinical Operations & Strategy

The benefits of working with an institutional biosafety committee in CGT research.

Insights from Bayer’s study review process showcases importance of incorporating feedback from a wider audience of stakeholders.

A more crowded space is presenting new challenges for stakeholders that must be addressed to improve efficiency.

Increased outreach is necessary to combat poor recruitment and large focus on patients near study centers.

Regional factors impact direct-to-patient modalities and bring the benefits of DCTs to life.

Considering caregiver-supported trials to improve patient retention and outcomes.

Lessons learned from COVID-19 vaccine trials.

Involvement of clinical endpoint committees in the adjudication process can improve reliability and robustness of data.

With poor retention of women in the biomedical workforce amid the pandemic, industry leaders in clinical research must step up to provide solutions.

Assessing the benefits of digital adherence monitoring for sites and patients.

In new age of digital, investigators must carefully create strategies to keep engagement high.

The answers to meeting biosimulation's growing demand for talent may lie in Africa.

Tony Clapsis, SVP, Clinical Trials Services, CVS, discusses recent advancements in the clinical trials space by CVS.

The intersection of academic research and clinical trials.

Becoming a preferred pharma partner for clinical trial sites.

2021 survey highlights challenges and opportunities for investigators, coordinators, and patients.

New proposals aim to create higher standards for trial regulation.

The need for specific capabilities to suit DCT business models is creating new challenges in team building, training, and development.

Four industry executives share insights during the Media and Analyst Roundtable at Veeva's R&D and Quality Summit Connect.

Some actions to consider for your next trial or submission.

How one CRO in India quickly implemented processes and technology to mitigate risk

Elderly patients achieved up to 98% compliance at 18 months on Phase III study.

Sponsors can simplify diaries by taking a closer look at the three common sources of complexity.

Higher costs headline list of new challenges faced by CROs and sponsors.

What the next generation medication management in clinical trials should entail and insights on smart technologies and synergistic partnerships—backed by real-life implementation use cases.